Pauline Rook, 73, from Somerset, started taking Turmeric+ Gold proactively as joint issues run in her family, and has been ...
Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in Phase I for Ependymoma.
BXQ-350 is under clinical development by Bexion Pharmaceuticals and currently in Phase II for Malignant Glioma.
In today’s fast-paced world, maintaining optimal cognitive function has become paramount. Whether juggling work deadlines, ...
Equities research analysts at StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the ...
Together, these assets hold promise for advancing treatment across a range of solid tumors,” said Lai Wang, Ph.D., Global Head of R&D ... for its proprietary phospholipid ether drug conjugate ...
This anionic phospholipid, normally oriented within the cell membrane to face internally, flips during cell activation to expose its head group externally. Because this phospholipid is essential for ...
Identical quantities of phospholipid and glycerolipid species ... specific specificities for both the lysophospholipid polar head group and the fatty acyl-CoAs. If it is the case that the exact ...
the Company’s investigational IV phospholipid substrate replacement therapy, as a source of choli TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in ...
At the beginning of May, Pfizer spun back out Esperion Therapeutics, which it had originally purchased for $1.3 billion in March 2004. Since the acquisition, most of Esperion's promising pipeline ...
State Key Laboratory of Biocontrol, School of Life Sciences, Guangdong Province Key Laboratory for Pharmaceutical Functional Genes, Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai ...